These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24795010)

  • 1. From breaking bad to worse: exploiting homologous DNA repair deficiency in cancer.
    Hemann MT
    Cancer Discov; 2014 May; 4(5):516-8. PubMed ID: 24795010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic lethality in DNA repair network: A novel avenue in targeted cancer therapy and combination therapeutics.
    Bhattacharjee S; Nandi S
    IUBMB Life; 2017 Dec; 69(12):929-937. PubMed ID: 29171189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nucleases in homologous recombination as targets for cancer therapy.
    Bartosova Z; Krejci L
    FEBS Lett; 2014 Aug; 588(15):2446-56. PubMed ID: 24928444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
    Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J
    Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data.
    Chartron E; Theillet C; Guiu S; Jacot W
    Crit Rev Oncol Hematol; 2019 Jan; 133():58-73. PubMed ID: 30661659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.
    Middleton FK; Patterson MJ; Elstob CJ; Fordham S; Herriott A; Wade MA; McCormick A; Edmondson R; May FE; Allan JM; Pollard JR; Curtin NJ
    Oncotarget; 2015 Oct; 6(32):32396-409. PubMed ID: 26486089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homologous recombination repair deficiency as a therapeutic target in sarcoma.
    Oza J; Doshi SD; Hao L; Musi E; Schwartz GK; Ingham M
    Semin Oncol; 2020 Dec; 47(6):380-389. PubMed ID: 33183763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular pathways: exploiting tumor-specific molecular defects in DNA repair pathways for precision cancer therapy.
    Dietlein F; Reinhardt HC
    Clin Cancer Res; 2014 Dec; 20(23):5882-7. PubMed ID: 25451105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-homologous DNA end joining in anticancer therapy.
    Pastwa E; Malinowski M
    Curr Cancer Drug Targets; 2007 May; 7(3):243-50. PubMed ID: 17504121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of Cancer.
    Velic D; Couturier AM; Ferreira MT; Rodrigue A; Poirier GG; Fleury F; Masson JY
    Biomolecules; 2015 Nov; 5(4):3204-59. PubMed ID: 26610585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches.
    Dietlein F; Thelen L; Reinhardt HC
    Trends Genet; 2014 Aug; 30(8):326-39. PubMed ID: 25017190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP inhibitors--current status and the walk towards early breast cancer.
    Glendenning J; Tutt A
    Breast; 2011 Oct; 20 Suppl 3():S12-9. PubMed ID: 22015278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the DNA double-strand break repair and its therapeutic implications.
    Ray U; Raghavan SC
    DNA Repair (Amst); 2021 Oct; 106():103177. PubMed ID: 34325086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA repair and synthetic lethality.
    Guo GS; Zhang FM; Gao RJ; Delsite R; Feng ZH; Powell SN
    Int J Oral Sci; 2011 Oct; 3(4):176-9. PubMed ID: 22010575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FEN1 endonuclease as a therapeutic target for human cancers with defects in homologous recombination.
    Guo E; Ishii Y; Mueller J; Srivatsan A; Gahman T; Putnam CD; Wang JYJ; Kolodner RD
    Proc Natl Acad Sci U S A; 2020 Aug; 117(32):19415-19424. PubMed ID: 32719125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homologous Recombination-Mediated DNA Repair and Implications for Clinical Treatment of Repair Defective Cancers.
    Reilly NM; Yard BD; Pittman DL
    Methods Mol Biol; 2019; 1999():3-29. PubMed ID: 31127567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-Strand DNA Break Repair in Mycobacteria.
    Glickman MS
    Microbiol Spectr; 2014 Oct; 2(5):. PubMed ID: 26104351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting homologous recombination-mediated DNA repair in cancer.
    Carvalho JF; Kanaar R
    Expert Opin Ther Targets; 2014 Apr; 18(4):427-58. PubMed ID: 24491188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mre11 Is Essential for the Removal of Lethal Topoisomerase 2 Covalent Cleavage Complexes.
    Hoa NN; Shimizu T; Zhou ZW; Wang ZQ; Deshpande RA; Paull TT; Akter S; Tsuda M; Furuta R; Tsutsui K; Takeda S; Sasanuma H
    Mol Cell; 2016 Nov; 64(3):580-592. PubMed ID: 27814490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.